New Molecular Axis Drives Excess Blood Sugar in Type 2 Diabetes

Type 2 diabetes (T2D) is driven largely by uncontrolled hepatic glucose production, most of which stems from excessive gluconeogenesis. Despite decades of research, the epigenetic mechanisms that fine-tune gluconeogenic gene expression in response to nutritional and hormonal signals remain incompletely understood. This study identifies a previously unrecognized regulatory axis — HNF4α → TET2 → FBP1 — that sits at the heart of this process.

The researchers first established that TET2, a DNA dioxygenase best known for its role in hematologic cancers, is upregulated in mouse liver under both overnight fasting (16 hours) and high-fat diet (HFD) feeding (11 days and 12 weeks). Using HepG2 cells and primary mouse hepatocytes, they showed that TET2 overexpression increases glucose output, while TET2 knockout suppresses it even under glucagon stimulation. Whole-body Tet2-knockout mice displayed significantly improved glucose tolerance, enhanced insulin sensitivity, and lower post-glucose insulin secretion compared to wild-type controls, with no difference in body weight — pointing to a liver-specific metabolic effect rather than an obesity-driven one.

Mechanistically, the team demonstrated that the nuclear receptor HNF4α physically recruits TET2 to the promoter of FBP1, the rate-limiting gluconeogenic enzyme that converts fructose-1,6-bisphosphate to fructose-6-phosphate. TET2 then catalyzes oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) at this promoter, reducing DNA methylation and activating FBP1 transcription. Glucagon signaling amplifies this process. Importantly, FBP1 rescue experiments confirmed that the pro-gluconeogenic effect of TET2 is mediated primarily through FBP1.

The study also provides a molecular explanation for part of metformin's therapeutic mechanism. Metformin treatment increases phosphorylation of HNF4α at serine 313 (Ser313). This phosphorylation event disrupts the HNF4α–TET2 protein–protein interaction, preventing TET2 recruitment to the FBP1 promoter, restoring promoter methylation, and reducing FBP1 expression. In HFD mouse models, hepatic TET2 overexpression worsened glucose homeostasis, while TET2 knockdown ameliorated it — effects that were blunted or reversed by FBP1 manipulation, confirming the axis operates in vivo.

These findings position TET2 as an epigenetic amplifier of gluconeogenesis that is activated by fasting and metabolic stress, and suppressed by metformin via HNF4α phosphorylation. The work opens the door to targeting TET2 or the HNF4α–TET2 interaction as a novel strategy for T2D management, particularly in patients with suboptimal metformin response.